On November 14, Legend Biotech fell 5.37% in Regular Trading, trading at $17.5 per share, with turnover of $40.1981 million.
The move was tied to continued post-earnings target price reductions and a fresh rating action from sell-side analysts. The latest update showed Evercore ISI downgrading the stock to In Line, after earlier cuts from RBC to $50, Morgan Stanley to $43, Oppenheimer to $25, and Barclays to $61.
Background results released on November 10 were mixed: third-quarter net profit reached $51.7 million, reversing from a year-earlier loss, while CARVYKTI net sales rose 36% year over year to about $710 million. However, quarterly revenue of $359.5 million came in slightly below market expectations, helping drive the cautious analyst response despite improved profitability.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments